Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies

Multiple Sclerosis Journal

Volumn 18, Issue 4, 2012, Pages 506-509

  Pilz, G ^a   Harrer, A ^a   Oppermann, K ^a   Wipfler, P ^a   Golaszewski, S ^a   Afazel, S ^a   Haschke Becher, E ^a   Trinka, E ^a   Kraus, J ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

alpha 4 integrin; multiple sclerosis; natalizumab; neutralizing antibodies

Indexed keywords

NATALIZUMAB; NEUTRALIZING ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MEASUREMENT; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL;

EID: 84859415460     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511423650     Document Type: Article

References (10)

1. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992 ; 356: 63-66
2. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003 ; 348: 15-23
3. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 ; 354: 899-910
4. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007 ; 69: 1391-1403
5. Wipfler P, Oppermann K, Pilz G, Afazel S, Haschke-Becher E, Harrer A, et al. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. Mult Scler. 2011 ; 17: 16-23
6. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 ; 58: 840-846
7. Kraus J, Oschmann P, Engelhardt B, Schiel C, Hornig C, Bauer R, et al. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol Scand. 1998 ; 98: 102-109
8. Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M, et al. Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol. 2010 ; 227: 190-194
9. Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol. 2006 ; 59: 748-754
10. Stüve O, Marra CM, Bar-Or A, Niino M, Cravers PD, Cepok S, et al. Altered Cd4+/CD8+ T cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006 ; 63: 1383-1387